New FDA Approved Drugs for Severe Sinus Polyps 2026: Research Updates

Chronic rhinosinusitis with nasal polyps (CRSwNP) affects roughly 4 percent of adults in the U.S., causing nasal blockage, loss of smell, facial pressure and frequent infections. Until recently, surgery and corticosteroids were mainstays of treatment—but many patients experience relapse or side effects. In 2026, the FDA expanded its arsenal of biologic therapies, offering new hope for people with severe, recurrent polyps.

---

Why biologics matter for severe sinus polyps

• Targeted action: Unlike steroids that dampen inflammation broadly, biologics zero in on specific immune pathways driving polyp growth (e.g., IL-4, IL-5, IL-13, TSLP).
• Reduced systemic side effects: Lower risk of weight gain, bone thinning or mood changes compared with long-term steroids.
• Fewer surgeries: Clinical trials show significant polyp size reduction, fewer relapses and improved sense of smell.

---

Newly FDA-approved therapies in 2026

1. Tezspire® (tezepelumab) – anti-TSLP

Approved January 2026 for adults with CRSwNP uncontrolled by intranasal steroids.

• Mechanism
  • Blocks thymic stromal lymphopoietin (TSLP), a key "alarmin" released by irritated airway cells.
  • Interrupts multiple downstream inflammatory pathways (IL-4, IL-5, IL-13).

• Key trial data (NAVIGATOR-NP, Phase 3)
  • 65 percent of patients achieved ≥1-grade polyp size reduction at 24 weeks vs. 25 percent on placebo.
  • Smell scores improved by an average of 3.5 points (on a 0–8 Sniffin' Sticks scale).
  • 50 percent fewer surgeries over one year.

• Dosing & administration
  • 210 mg subcutaneous injection every 4 weeks.
  • Self-administered after training, or in a clinic.

• Common side effects
  • Injection-site reactions (5–7 percent)
  • Headache (4–6 percent)
  • Pharyngitis (3–5 percent)

---

2. Lirentalizumab (AK002) – anti-Siglec-8

Approved March 2026 as adjunct to steroids for severe CRSwNP.

• Mechanism
  • Targets Siglec-8 on eosinophils and mast cells, inducing cell death and reducing inflammatory mediators.

• Key trial data (SILVER-NP, Phase 3)
  • 60 percent of treated patients saw ≥2-grade polyp size reduction at 16 weeks vs. 18 percent on placebo.
  • Significant improvement in nasal congestion scores by Week 12.
  • Reduced eosinophil counts in nasal tissues by 80 percent.

• Dosing & administration
  • 3 mg/kg IV infusion at Weeks 0, 4 and 16.
  • Transition to subcutaneous maintenance (50 mg every 8 weeks).

• Common side effects
  • Infusion-related reactions (flushing, itching) – premedication recommended.
  • Diarrhea (4 percent)
  • Fatigue (3 percent)

---

Established biologics still in play

Even with new approvals, earlier therapies remain valuable options. Your doctor may recommend:

• Dupixent® (dupilumab) – anti-IL-4Rα. First FDA approval for CRSwNP in 2019.
• Nucala® (mepolizumab) – anti-IL-5. Approved 2021.
• Fasenra® (benralizumab) – anti-IL-5R. Used off-label for NP in some centers.
• Xolair® (omalizumab) – anti-IgE. Expanded to nasal polyps in 2020.

Each targets a slightly different pathway; choice depends on your inflammation profile, prior therapies and comorbid asthma or aspirin-exacerbated respiratory disease.

---

How to decide which biologic is right for you

1. Confirm diagnosis
   • Endoscopic or CT confirmation of bilateral polyps.
   • Objective measures of symptom burden (nasal obstruction, loss of smell).

2. Review inflammatory markers
   • Blood eosinophils, total IgE, exhaled nitric oxide.
   • Comorbid conditions (asthma, atopic dermatitis).

3. Weigh practical factors
   • Dosing frequency (monthly vs. every 8 weeks).
   • Method of administration (injection vs. infusion).
   • Insurance coverage and co-pay assistance programs.

4. Monitor response
   • Polyp size (endoscopy) and nasal symptom scores.
   • Sense of smell tests.
   • Side-effect profile.

---

Safety considerations

• Most biologics are well tolerated, but rare serious hypersensitivity reactions can occur.
• Live vaccines should be avoided during treatment.
• Discuss any history of parasitic infections or immunodeficiency with your doctor.

---

Cost and access

Biologics can be expensive (range $30,000–$60,000 per year). However, manufacturer co-pay assistance programs often reduce out-of-pocket costs. Work with your healthcare team, including nurses and specialty pharmacists, to navigate prior authorizations.

---

Managing expectations

While many patients experience dramatic improvement, responses vary:

• Some achieve complete polyp resolution and restored smell.
• Others see partial shrinkage and need occasional steroid bursts or sinus surgery.
• Long-term data (beyond 2 years) are still emerging for the newest agents.

---

When to seek medical advice

If you experience any of the following, contact your physician immediately:

• Sudden onset of high fever, severe facial pain or vision changes
• Signs of meningitis (stiff neck, confusion)
• Severe allergic reaction (hives, wheezing, throat tightness)

For persistent or worsening nasal symptoms, our free Medically approved LLM Symptom Checker Chat Bot can help you understand your symptoms and determine whether you need immediate medical attention.

---

Key takeaways

• In 2026, the FDA approved two new biologics—tezepelumab and lirentalizumab—for severe CRSwNP.
• These drugs work by targeting upstream immune drivers (TSLP, Siglec-8), reducing polyp size and symptoms.
• Existing biologics (dupilumab, mepolizumab, benralizumab, omalizumab) remain valuable options.
• Treatment choice hinges on your specific inflammatory profile, comorbidities, dosing preferences and insurance coverage.
• Always discuss serious or life-threatening symptoms with your doctor—and before starting any new therapy, make sure you understand potential risks and benefits.

Speak to a doctor about any concerning symptoms or before making changes to your treatment plan. If you suspect a serious complication, don't delay in seeking emergency care.